Key statistics
As of last trade Ardelyx Inc (ARDX*:MEX) traded at 128.80, -7.14% below its 52-week high of 138.70, set on Jan 09, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 128.40 |
|---|---|
| High | 128.80 |
| Low | 128.40 |
| Bid | -- |
| Offer | -- |
| Previous close | 128.80 |
| Average volume | -- |
|---|---|
| Shares outstanding | 242.97m |
| Free float | 234.96m |
| P/E (TTM) | -- |
| Market cap | 1.77bn USD |
| EPS (TTM) | -0.2364 USD |
Data delayed at least 20 minutes, as of Jan 15 2026 11:30 GMT.
More ▼
- Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
- Ardelyx Receives New Patent for Tenapanor
- First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
- Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
- Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
- Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
- Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
- Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
- Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
More ▼
